10x Genomics Elects Directors at Annual Meeting

The latest announcement is out from 10x Genomics ( (TXG) ).

On June 3, 2025, 10x Genomics held its annual stockholders’ meeting via webcast, with a quorum of approximately 87.7% of eligible votes. The meeting resulted in the election of two Class III directors for a three-year term and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (TXG) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on 10x Genomics stock, see the TXG Stock Forecast page.

Spark’s Take on TXG Stock

According to Spark, TipRanks’ AI Analyst, TXG is a Neutral.

10x Genomics faces several challenges, including profitability issues and uncertainties in the U.S. funding environment, leading to a negative valuation perspective. While strong consumables growth and improved cash management are positives, the overall sentiment remains cautious due to the withdrawal of full-year guidance and weak technical momentum.

To see Spark’s full report on TXG stock, click here.

More about 10x Genomics

10x Genomics operates in the biotechnology industry, focusing on developing advanced genomic analysis solutions. The company is known for its innovative products that enable researchers to explore complex biological systems, with a strong market presence in the genomics sector.

Average Trading Volume: 3,608,429

Technical Sentiment Signal: Sell

Current Market Cap: $1.14B

See more insights into TXG stock on TipRanks’ Stock Analysis page.